Ireland· IE-PA-EU/1/17/1223/002
Vosevi 200 mg/50 mg/50 mg film-coated tablets
A direct acting antivirals product containing sofosbuvir + velpatasvir + voxilaprevir, registered in Ireland by Gilead Sciences Ireland UC.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
The record
At a glance
HPRA (Ireland)- Active substance
- Sofosbuvir + Velpatasvir + Voxilaprevir
- Manufacturer
- Gilead Sciences Ireland UC
- Country
- Ireland (IE)
- ATC code
- J05A
- ATC class
- DIRECT ACTING ANTIVIRALS
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberEU/1/17/1223/002
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Sofosbuvir + velpatasvir + voxilaprevir in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- IcelandVoseviGilead Sciences Ireland UC*
- NetherlandsVosevi 200 mg/50 mg/50 mg, filmomhulde tablettenGilead Sciences Ireland UC
- CzechiaVOSEVIGilead Sciences Ireland UC, Carrigtohill
- PolandVoseviGilead Sciences Ireland UC
- SwedenVosevi 200 mg/50 mg/50 mg Filmdragerad tablettGilead Sciences Ireland UC
- FinlandVoseviGilead Sciences Ireland UC
- CanadaVOSEVIGILEAD SCIENCES CANADA INC
- United StatesVoseviGilead Sciences, Inc.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Vosevi
- Liechtenstein · Vosevi
- Norway · Vosevi
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/75b67235-d0fb-419b-aba5-cdc0cfb0736e GET /v1/drugs/75b67235-d0fb-419b-aba5-cdc0cfb0736e?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Film-coated tablet",
"routes": [
"Oral use"
],
"source": "hpra",
"atc_all": [
"J05A"
],
"strength": null,
"pa_number": "EU/1/17/1223/002",
"substances": [
"Sofosbuvir",
"Velpatasvir",
"Voxilaprevir"
],
"legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Unknown",
"authorised_at": "21/04/2021",
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about sofosbuvir + velpatasvir + voxilaprevir.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.